Pre-made Valanafusp benchmark antibody ( Whole mAb Fusion, anti-INSR therapeutic antibody, Anti-CD220/HHF5 Antibody) for drug discovery and mechanism of action (MOA) research

Pre-Made Valanafusp biosimilar, Whole mAb Fusion, Anti-INSR Antibody: Anti-CD220/HHF5 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Valanafusp alpha is a BBB-penetrating form of IDUA, and is designed to deliver the IDUA enzyme to brain cells to reverse the accumulation of heparan sulfate (HS) GAGs and lysosomal inclusions. The primary therapeutic goal of valanafusp alpha therapy is stabilization of cognitive decline in severe MPSI.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-ab-608-1mg	1mg	Inquiry
GMP-Bios-ab-608-10mg	10mg	Inquiry
GMP-Bios-ab-608-100mg	100mg	Inquiry
GMP-Bios-ab-608-xmg	＞100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Valanafusp biosimilar, Whole mAb Fusion, Anti-INSR Antibody: Anti-CD220/HHF5 therapeutic antibody
INN Name	Valanafusp
Target	INSR
Format	Whole mAb Fusion
Derivation
Species Reactivity	Human
CH1 Isotype	IgG1
VD LC	Kappa
Highest_Clin_Trial (Jan '20)	Phase-II
Est. Status	Active
100% SI Structure	None
99% SI Structure	5kqv:PQ:CD/4zxb:CD
95-98% SI Structure	3loh:CD/2dtg:CD/3w14:CD:PQ
Year Proposed	2017
Year Recommended	2018
Companies	ArmaGen Technologies
Conditions Approved	na
Conditions Active	Mucopolysaccharidosis I
Conditions Discontinued	na
Development Tech	na